Bright Minds Biosciences (DRUG) KOL Event summary

Introduction and agenda

• The event, scheduled for November 6, 2025, featured updates on clinical programs for Prader-Willi Syndrome (PWS), including the Phase 2a NOVA study evaluating BMB-101, with presentations from scientific, clinical, and patient advocacy leaders.

• The agenda included an overview of PWS, unmet needs, scientific rationale for 5-HT2C agonists, clinical development plans, current treatment limitations, clinical assessment tools, and a Q&A session.

KOL background and credentials

• Presenters included Dr. Jennifer Miller (University of Florida), Dr. Theresa Strong (Foundation for Prader-Willi Research), and Elizabeth Roof (Vanderbilt University), each with decades of experience in PWS care and research, with Dr. Miller having over 500 PWS patients under care and Roof evaluating over 450 individuals.

• Dr. Theresa V. Strong is a founding member of the Foundation for Prader Willi Research and directs its grant program.

Market insights and analysis

• PWS affects about 10,000 patients in the U.S. and 400,000 globally, representing a $4.6 billion U.S. market opportunity.

• PWS is a rare genetic disorder affecting 1 in 15,000 live births, characterized by hyperphagia and significant neurobehavioral challenges.

• Current therapies, such as VYKAT, address only hyperphagia, leaving broader neurobehavioral symptoms largely untreated and highlighting a high unmet need.